Cardiac contractility modulators for hypertrophic cardiomyopathy
Candidate cardiac contractility modulators designed for hypertrophic cardiomyopathy by addressing heightened calcium sensitivity of cardiac myofilaments. The molecules have shown promise in in vitro and in vivo studies and are available for co-development, licensing, and pilot trial engagement.
Overview
This technology comprises candidate cardiac contractility modulators being developed for hypertrophic cardiomyopathy (HCM), a heart condition characterized by increased calcium sensitivity of cardiac myofilaments. The molecules are intended to modulate the heart's contractile response and address the underlying functional abnormality in HCM. Early in vitro and in vivo studies indicate that the candidate molecules may provide a solution to this disease mechanism.
Technical specifications
How it works:
- In HCM, cardiac myofilaments are abnormally sensitive to calcium, leading to excessive contraction and impaired relaxation.
- The candidate modulators are designed to influence cardiac contractility at the myofilament level, potentially normalizing contraction and improving heart function.
- The research also involves prostacyclin (PGI₂) and related arachidonic acid pathways, which are relevant to vascular health and blood flow regulation.
Key features:
- Candidate molecules identified for their effect on cardiac contractility
- Evidence from both in vitro and in vivo studies supports further development
- Potential therapeutic application in hypertrophic cardiomyopathy
- Mechanism centered on the calcium sensitivity of cardiac myofilaments
Technology readiness level
This technology is at an early, pre-clinical stage. The candidate molecules have shown promising results in in vitro and in vivo studies, but additional validation is needed to assess safety, efficacy, dosing, and translational potential in relevant disease models. The program is open to collaboration models including co-development, licensing, and pilot trial engagement to support further advancement.
About caykur
Caykur, legally known as Cay Isletmeleri Genel Mudurlugu, is a state-owned economic enterprise in Turkey that operates as a major entity in the nation's tea industry. Headquartered in Rize, it manages a extensive infrastructure that includes numerous tea processing factories, regional marketing directorates, and the Ataturk Tea and Garden Cultures Research Institute. The organization is responsible for developing tea agriculture in line with national policies, purchasing a significant portion of tea produced in the region, and producing, marketing, importing, and exporting various tea products. It operates with a mandate to balance economic efficiency and profitability while supporting Turkey's agricultural sector.
As the leader in the Turkish tea market, Caykur plays a central role for tea producers and consumers across the country. It provides essential support to tea farmers, including the purchasing of raw tea leaves, and maintains a substantial share of the domestic dry tea market. The organization is subject to regulation by the Ministry of Agriculture and Forestry and has been part of the Turkey Wealth Fund since 2017. By overseeing the end-to-end process from agricultural development to industrial processing and commercial distribution, Caykur serves as a cornerstone of the regional economy in Eastern Anatolia and remains a critical provider of tea products within Turkey.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.